ScoreHaematology

International Prognostic Scoring System for myelodysplastic syndromes (IPSS, 1997)

Classifies myelodysplastic syndrome risk by marrow blasts, karyotype and number of cytopenias.

Updated 31 October 2026

When to use it

Adults with untreated primary MDS, especially when a trial or older protocol requires the original IPSS.

What it needs

  • Bone marrow blastsOptions: < 5 % · 5–10 % · 11–20 % · 21–30 %
  • KaryotypeOptions: Good: normal, −Y alone, del(5q) alone or del(20q) alone · Intermediate: other abnormalities · Poor: complex (≥ 3 abnormalities) or chromosome 7 anomalies
  • Number of cytopeniasOptions: 0 or 1 · 2 or 3

The points for each answer and the automatic total are in the app.

How to interpret it

IPSS score
ResultInterpretation
< 0.5Low risk: median survival ≈ 5.7 years
0.5 to < 1.5Intermediate-1: median survival ≈ 3.5 years
1.5 to < 2.5Intermediate-2: median survival ≈ 1.2 years
≥ 2.5High risk: median survival ≈ 0.4 years

Practical tip

It has been superseded in practice by the IPSS-R (and IPSS-M); use it mainly for comparison with older studies.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top